Patents Assigned to Abic Biological Laboratories Teva, Ltd.
  • Patent number: 7858766
    Abstract: A nucleic acid sequence encoding a fragment of the adenovirus fiber capsid protein, a DNA construct including a replicable expression vector and at least one heterologous nucleic acid, and recombinant protein including fragment of the adenovirus fiber cpasid protein. The fragment comprises the C-terminal knob and part of the shaft domain of the fiber protein of these adenoviruses. The use of recombinant proteins as an active ingredient in vaccinating compositions for conferring to an animal immunity against a pathogenic infection by an adenovirus, and methods for vaccinating a domestic bird against a pathogenic adenoviral infection.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: December 28, 2010
    Assignee: Abic Biological Laboratories Teva Ltd.
    Inventors: Jacob Pitcovski, Elena Fingerut, Bezalel Gutter, Gilad Gallili, Amnon Michael
  • Patent number: 7462707
    Abstract: The present invention provides an isolated nucleic acid comprising a nucleotide sequence encoding a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima, or encoding a homolog of the polypeptide, or a complement of the nucleic acid and a method of producing a recombinant 250 kDa polypeptide of the same. The present invention also provides an isolated nucleic acid comprising a nucleotide sequence encoding an immunodominant portion of a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima having the amino acid sequence described herein, or encoding a homolog of the polypeptide, or a complement of the nucleic acid.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: December 9, 2008
    Assignees: University of Technology, Sydney, Abic Biological Laboratories Teva, Ltd.
    Inventors: David Witcombe, Nicholas C. Smith, Michael Wallach
  • Patent number: 7423137
    Abstract: The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: September 9, 2008
    Assignee: Abic Biological Laboratories Teva, Ltd.
    Inventors: Sabina I. Belli, Nicholas C. Smith, Michael Wallach